CRISPR Therapeutics Stock News

Vertex Pharmaceuticals is trying to commercialize its gene therapy exa-cel. Researchers found some disturbing evidence about certain possible side effects.

Using gene therapy, companies can change patients' DNA. One type of gene therapy, called CRISPR, largely mimics a method used by bacteria to fend off viruses.

CRISPR Therapeutics is cutting two of its more advanced candidates in favor of two next-generation ones. The company is also awaiting a key regulatory decision on Friday.

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock?

Based on early data from ongoing clinical studies, CRISPR (CRSP) has decided to focus on the development of its next-generation CAR T pipeline and discontinue its first-generation CAR T candidates.

CRISPR Therapeutics may soon generate its first product revenue. Invitae, making progress in its recovery plan, could climb if it meets its goals.

Now is a great time to consider stocks that may boost your portfolio, both in the new investing year and over time. Companies offering steady earnings growth -- or the promise of earnings growth -- ar

AI isn't just revolutionizing biotech; it's reinventing it. From predicting diseases to accelerating drug discovery, AI is turning data into medical gold, reshaping how we approach healthcare innovati

ARK Innovation ETF (ARKK), which provides thematic multi-cap exposure to innovation across sectors, has gained 35.2%, becoming the best-performing ETF of November.

CRISPR and Vertex recently earned approval for a gene-editing treatment, Casgevy. Casgevy shows the potential of CRISPR's platform and should improve its financial results.

These companies are just getting started along the path of revenue growth. Their technologies -- gene editing and organism engineering -- help them stand out from the crowd.

In the dynamic realm of modern medicine, biotech stocks have effectively emerged at the forefront of a transformation. These innovative players are steering us towards a new era of medical marvels wit

Does CRISPR Therapeutics AG (CRSP) have what it takes to be a top stock pick for momentum investors? Let's find out.

Intellia Therapeutics and CRISPR Therapeutics are considered the top two players in the CRISPR space in the next 1 to 3 years. NTLA focuses on in vivo gene editing and has a comprehensive pipeline tar

Amazon has plenty of room to grow despite its already huge size. CRISPR Therapeutics is at a pivotal point, with U.S. approvals for its lead candidate potentially on the way.